Quick Takeaways: Why It Matters? The FDA’s Emergency Use Authorization for Simparica Trio to treat New World screwworm (NWS) larvae in dogs gives veterinarians a convenient, oral option that can be used alongside existing livestock tools (e.g., Dectomax...
Featured Article Cover Story Product launch Clinical data Retail pharmacy FDA Launches Animal Drug Manufacturing Pilot Regulatory update The FDA’s Center for Veterinary Medicine has launched a pilot program to speed review of animal drug applications when both the finished product and acti...
Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
Featured Article Understanding Pet Food Labels: What Every Pet Owner Should Know Cover Story Investment Product Launch Product Expansion Partnership Clinical Study Regulatory Updates Zoetis Acquires VitalRADS Acquisition Zoetis has agreed to acquire VitalRADS to expand its veterinary diagn...
Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? Zoetis’s acquisition of VitalRADS is a strategic move to consolidate and scale veterinary diagnostics by bundling AI-powered workflow tools, teleradiology, mobile and outpatient imaging, and cloud-based storage under one platform, which should a...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways Why It Matters? A new proprietary CNS asset from Orion, exclusively commercialized by Zoetis in the US, that taps into fast‑growing demand for medical management of canine anxiety and should expand the addressable market beyond situational noise phobia toward mo...
Quick Takeaways Why It Matters? Zoetis vaults into genomics leadership, fusing Neogen’s lab network with its biologics portfolio to dominate precision breeding and herd management. Deal crushes smaller agtech players, handing ranchers data-driven productiv...
